MarketPulse

clinical trial design

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

uniQure Stock Collapses 49% Amid FDA Dispute; Class Action Lawsuit Seeks Lead Plaintiffs

uniQure stock plunged 49% after FDA disagreement on gene therapy trial design. Investors with losses eligible to join class action lawsuit by April 2026.
QUREstock declineinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Gene Therapy Firm uniQure Faces Securities Investigation Over FDA Data Dispute

uniQure faces securities investigation after FDA publicly disputed the company's claims about regulatory guidance for gene therapy candidate AMT-130, with April 2026 deadline for investor class action.
QUREstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Gene Therapy Crash: QURE Faces Securities Probe After FDA Alleges Data Distortion

Hagens Berman investigates $QURE over FDA allegations of misrepresented gene therapy data and manipulated study design. Stock tumbled 49% following November 3 FDA rebuttal.
QUREstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Gene Therapy Firm uniQure Faces Securities Lawsuit Over Alleged FDA Data Distortion

Hagens Berman investigates $QURE for misrepresenting FDA interactions on gene therapy AMT-130. Stock crashed 49% after FDA publicly rebuked company's data claims.
QUREinvestor lossessecurities class action